Hadean Ventures

What they fund

Hadean Ventures funds science-driven healthcare and biotechnology companies, particularly those with unique platform technologies and strong management teams. They invest across sectors and stages, backing solutions that address complex, real-world challenges and unmet needs [1].

Investment thesis

Hadean Ventures is a European venture capital firm focused on science-driven innovation, particularly in healthcare and biotechnology. The firm leverages deep scientific and technical expertise to support healthcare and life sciences companies, aiming to generate strong financial returns while making a meaningful impact by investing in the future of healthcare [1]. They prioritize unique platform technologies and high-quality management teams, as evidenced by their investment in Themis Bioscience, where the uniqueness of the measles-based platform was a key factor [1].

• Science-Driven Healthcare — Hadean Ventures acts as a European partner for science-driven innovation, leveraging deep scientific and technical expertise to support healthcare and life sciences companies [Profile].
• Impact & Returns — The firm’s purpose is to generate strong financial returns while making a meaningful impact by investing in the future of healthcare [1].
• Platform & Technology Validation — The firm prioritizes unique platform technologies and high-quality management teams, as evidenced by its investment in Themis Bioscience, where the uniqueness of the measles-based platform was a key factor [1].

Credibility: The firm's website states its focus on science-driven innovation and impact, and mentions its investment in Themis Bioscience as an example of backing unique platform technologies [1].

Value add

Hadean Ventures provides deep scientific and technical expertise, as well as a platform for validation and support. They also have a strong focus on impact and ESG, with a dedicated Impact & ESG Manager on their team [1].

Fit verdict: A strong fit for science-driven healthcare and biotechnology companies seeking European venture capital and scientific expertise.

Founder diligence script:

• What specific scientific or technical expertise can Hadean Ventures provide to our company?
• How does Hadean Ventures measure and report on impact and ESG metrics?
• What is the typical decision-making process and timeline for investments at Hadean Ventures?

Portfolio focus

The portfolio clusters around healthcare and biotechnology, with a focus on science-driven innovation. Specific portfolio companies are not listed in the provided documents, but Themis Bioscience is mentioned as an example of a unique platform technology investment [1].

Notable investments & exits

• Emergence Therapeutics — A European biopharmaceutical company advancing a nectin-4 antibody-drug conjugate for solid tumour oncology; this investment resulted in an exit.
• Cardior Pharmaceuticals — A leading clinical-stage biopharmaceutical company developing RNA therapeutics for cardiac disease; acquired by Novo Nordisk in March 2024.
• Abliva — A Swedish drug development company focused on treatments for rare primary mitochondrial diseases; acquired by Pharming in 2025.
• Themis Bioscience — Received a EUR 40 million Series D financing round in September 2019, co-led by Hadean Ventures and Farallon Capital, to support the pivotal Phase 3 Chikungunya vaccine trial and oncology expansion.
• Active Portfolio Highlights — Current portfolio includes AB (Abliva), Actithera (radiopharmaceuticals), Alex Therapeutics (AI mental health), ARTHEx Biotech (RNA treatments), Attgeno (pulmonary hypertension), CardioMech (mitral valve repair), Complement Therapeutics (ophthalmology), Contineum Therapeutics (neurology), Galecto (fibrosis/oncology), Gesynta Pharma (endometriosis), Neuro Event Labs (AI seizure monitoring), Nisonic (neurological ultrasound), Oncoinvent (radiopharmaceuticals), Ribbon Bio (gene therapy), SAGA Diagnostics (liquid biopsies), and SciRhom (immunology).

Strategic implications

Hadean Ventures' focus on science-driven healthcare and biotechnology positions it as a key player in the European life sciences ecosystem. Its deep scientific expertise and platform for validation are significant advantages for portfolio companies. However, the lack of disclosed co-investors and exits may indicate a relatively young or niche track record. A signal that would change the read would be the disclosure of major exits or a significant increase in AUM.

The firm's emphasis on impact and ESG aligns with growing investor demand for responsible investing, potentially attracting LPs and portfolio companies with strong sustainability profiles.

The firm's Nordic emphasis may limit its deal flow in other European markets, but could provide a competitive advantage in the Nordic region.

Where they could go further

Hadean Ventures could benefit from disclosing more details about its co-investors and notable exits to build credibility and attract more deal flow.

The firm could expand its geographic focus beyond Europe to tap into global opportunities in healthcare and biotechnology.

Hadean Ventures could enhance its value proposition by providing more hands-on support to portfolio companies, such as operational expertise or access to strategic partnerships.